TY - JOUR
T1 - Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy
T2 - A pooled analysis of controlled studies
AU - Roth, Eli M.
AU - Rosenson, Robert S.
AU - Jones, Peter H.
AU - Davidson, Michael H.
AU - Kelly, Maureen T.
AU - Setze, Carolyn M.
AU - Lele, Aditya
AU - Thakker, Kamlesh
N1 - Funding Information:
Financial support was provided by Abbott (Abbott Park, IL, USA) and AstraZeneca (Wilmington, DE, USA). Dr. Roth discloses that he has received clinical trial funding from Abbott, AstraZeneca, and other major pharmaceutical companies; he is a consultant for Abbott and serves on the speaker’s bureau for Merck. Dr. Rosenson discloses that he is consultant for Abbott, Daiichi-Sankyo, Genentech, Roche, Grain Food Board, LipoScience, and Sanofi Aventis. He is a stockholder in LipoScience, Inc. Dr Jones discloses that he has received honoraria from AstraZeneca, Merck, Abbott, and Daiichi-Sankyo for being a speaker and honoraria from AstraZeneca, Merck, Abbott, Roche/Genentech, and Atherotec for consulting. Dr. Davidson discloses that he has no stock ownership in Radiant Research, a Division of Swiss BioScience, or in any of the following companies. He has received grant/research support, honoraria, has served as consultant/speakers’ bureau for the following companies in the past 3 years: speakers’ bureau for Abbott, AstraZeneca, GlaxoSmithKline, and Merck; advisory board/consultant for Abbott, Aegerion, Amgen, AstraZeneca, Atherotech, Daiichi-Sankyo, DTC MD, Esperion, Omthera, GlaxoSmithKline, iMD (Intelligent Medical Decisions), Kinemed, LipoScience, Merck, Novo Nordisk, Roche, Sanofi-Aventis, Synarc, Takeda, and Vindico Medical Education; grant/research from Abbott, AstraZeneca, Daiichi-Sankyo, Merck, and Roche; and board of directors for DTC MD, Omthera, Professional Evaluation, Inc. Medical Education Company, and Sonogene. Dr. Maureen T. Kelly, Dr. Kamlesh Thakker, Carolyn M. Setze, and Aditya Lele are Abbott employees and stockholders.
PY - 2012/11
Y1 - 2012/11
N2 - Background: Goal/desirable lipid levels are underachieved in patients with mixed dyslipidemia. These patients may have substantial residual risk of cardiovascular disease even while receiving optimal LDL-C-lowering therapy and may require additional therapy to improve multiple lipid/lipoprotein levels. Objective: To evaluate attainment of goal/desirable levels of lipids/lipoproteins after 12-week treatment with combination rosuvastatin + fenofibric acid versus rosuvastatin monotherapy. Methods: This was a post hoc analysis of patients with mixed dyslipidemia who enrolled in one of two randomized controlled trials, and were treated (N = 2066) with rosuvastatin (5, 10, or 20 mg), fenofibric acid 135 mg, or rosuvastatin + fenofibric acid for 12 weeks. Data were pooled across doses of rosuvastatin as monotherapy and combination therapy. Results: Compared with rosuvastatin monotherapy, combination therapy had comparable effects in achieving risk-stratified LDL-C goals; however, measures of total atherogenic burden were improved because significantly greater percentages of patients attained non-HDL-C goal in high- (62.9% vs 50.4%, P =.006) and moderate-risk groups (87.6% vs 80.4%, P =.016) and apolipoprotein B (ApoB) <90 mg/dL in high-risk group (59.8% vs 43.8%, P <.001). In the overall population, more patients treated with the combination therapy achieved desirable levels of HDL-C >40/50 mg/dL in men/women (P <.001), triglycerides <150 mg/dL (P <.001), and ApoB <90 mg/dL (P <.001), compared with rosuvastatin monotherapy. Furthermore, combination therapy resulted in significantly greater percentages of patients achieving simultaneous specified levels of LDL-C + non-HDL-C (P <.015); LDL-C + HDL-C + TG (P <.001); and LDL-C + HDL-C + triglycerides + non-HDL-C + ApoB (P <.001), compared with rosuvastatin monotherapy. Conclusion: Rosuvastatin + fenofibric acid may be more efficacious than rosuvastatin alone in patients with mixed dyslipidemia.
AB - Background: Goal/desirable lipid levels are underachieved in patients with mixed dyslipidemia. These patients may have substantial residual risk of cardiovascular disease even while receiving optimal LDL-C-lowering therapy and may require additional therapy to improve multiple lipid/lipoprotein levels. Objective: To evaluate attainment of goal/desirable levels of lipids/lipoproteins after 12-week treatment with combination rosuvastatin + fenofibric acid versus rosuvastatin monotherapy. Methods: This was a post hoc analysis of patients with mixed dyslipidemia who enrolled in one of two randomized controlled trials, and were treated (N = 2066) with rosuvastatin (5, 10, or 20 mg), fenofibric acid 135 mg, or rosuvastatin + fenofibric acid for 12 weeks. Data were pooled across doses of rosuvastatin as monotherapy and combination therapy. Results: Compared with rosuvastatin monotherapy, combination therapy had comparable effects in achieving risk-stratified LDL-C goals; however, measures of total atherogenic burden were improved because significantly greater percentages of patients attained non-HDL-C goal in high- (62.9% vs 50.4%, P =.006) and moderate-risk groups (87.6% vs 80.4%, P =.016) and apolipoprotein B (ApoB) <90 mg/dL in high-risk group (59.8% vs 43.8%, P <.001). In the overall population, more patients treated with the combination therapy achieved desirable levels of HDL-C >40/50 mg/dL in men/women (P <.001), triglycerides <150 mg/dL (P <.001), and ApoB <90 mg/dL (P <.001), compared with rosuvastatin monotherapy. Furthermore, combination therapy resulted in significantly greater percentages of patients achieving simultaneous specified levels of LDL-C + non-HDL-C (P <.015); LDL-C + HDL-C + TG (P <.001); and LDL-C + HDL-C + triglycerides + non-HDL-C + ApoB (P <.001), compared with rosuvastatin monotherapy. Conclusion: Rosuvastatin + fenofibric acid may be more efficacious than rosuvastatin alone in patients with mixed dyslipidemia.
KW - Combination therapy
KW - Fenofibric acid
KW - Lipoproteins
KW - Mixed dyslipidemia
KW - Rosuvastatin
UR - https://www.scopus.com/pages/publications/84870302337
U2 - 10.1016/j.jacl.2012.02.002
DO - 10.1016/j.jacl.2012.02.002
M3 - Article
C2 - 23312049
AN - SCOPUS:84870302337
SN - 1933-2874
VL - 6
SP - 534
EP - 544
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 6
ER -